Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
6.5 SEK
91.82 M SEK
597.54 M SEK
24.49 M
About XVIVO PERFUSION AB
Sector
Industry
CEO
Christoffer Rosenblad
Website
Headquarters
Gothenburg
Founded
1998
ISIN
SE0004840718
FIGI
BBG00JHW7PD2
Xvivo Perfusion AB is a medical technology company. It involves in developing and marketing solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation. Its products include XPS, XPS Disposable Kit, Steen Solution, Organ Chamber, Lung Cannula Set, Perfadex and Silicone Tubing Set. It operates through the Durable Goods and Non-Durable Goods segments. The Durable Goods segment includes sales and rental revenues from machines. The Non-Durable Goods segment covers sales of goods and services that are not durable goods. The company was founded by Magnus Nilsson on December 17, 1998 and is headquartered in Gothenburg, Sweden.
XVIVO Fibonacci levels and volume analysis for ConnyXVIVO Fibonacci levels and volume analysis.
Weekly chart
Simple short term analysis of XVIVO for Conny10 minute quick technical analysis on XVIVO.
Due to the monetary easing (Corona) and a 12 year bull market, the markets are over heated. The next correction will be brutal.
The equity markets in general seems like super high risk to me at the moment, but I trade crypto not equities so don't liste
Simple XVIVO long term analysis for ConnyChart is using Log scale (used for multi year analysis).
Respects the fib channel extremely well.
www.investopedia.com
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0RKL is 466.5 SEK — it has decreased by −0.04% in the past 24 hours. Watch XVIVO PERFUSION AB NPV stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange XVIVO PERFUSION AB NPV stocks are traded under the ticker 0RKL.
0RKL stock has fallen by −0.97% compared to the previous week, the month change is a 0.55% rise, over the last year XVIVO PERFUSION AB NPV has showed a 50.73% increase.
We've gathered analysts' opinions on XVIVO PERFUSION AB NPV future price: according to them, 0RKL price has a max estimate of 584.00 SEK and a min estimate of 480.00 SEK. Watch 0RKL chart and read a more detailed XVIVO PERFUSION AB NPV stock forecast: see what analysts think of XVIVO PERFUSION AB NPV and suggest that you do with its stocks.
0RKL reached its all-time high on Jul 19, 2024 with the price of 545.0 SEK, and its all-time low was 83.5 SEK and was reached on Apr 13, 2018. View more price dynamics on 0RKL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0RKL stock is 3.65% volatile and has beta coefficient of 1.16. Track XVIVO PERFUSION AB NPV stock price on the chart and check out the list of the most volatile stocks — is XVIVO PERFUSION AB NPV there?
Today XVIVO PERFUSION AB NPV has the market capitalization of 14.69 B, it has decreased by −0.55% over the last week.
Yes, you can track XVIVO PERFUSION AB NPV financials in yearly and quarterly reports right on TradingView.
XVIVO PERFUSION AB NPV is going to release the next earnings report on Jan 28, 2025. Keep track of upcoming events with our Earnings Calendar.
0RKL earnings for the last quarter are 2.75 SEK per share, whereas the estimation was 0.83 SEK resulting in a 231.78% surprise. The estimated earnings for the next quarter are 1.41 SEK per share. See more details about XVIVO PERFUSION AB NPV earnings.
XVIVO PERFUSION AB NPV revenue for the last quarter amounts to 198.00 M SEK, despite the estimated figure of 205.77 M SEK. In the next quarter, revenue is expected to reach 219.49 M SEK.
0RKL net income for the last quarter is 85.82 M SEK, while the quarter before that showed 27.19 M SEK of net income which accounts for 215.58% change. Track more XVIVO PERFUSION AB NPV financial stats to get the full picture.
No, 0RKL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 150.00 employees. See our rating of the largest employees — is XVIVO PERFUSION AB NPV on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. XVIVO PERFUSION AB NPV EBITDA is 134.56 M SEK, and current EBITDA margin is 11.61%. See more stats in XVIVO PERFUSION AB NPV financial statements.
Like other stocks, 0RKL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade XVIVO PERFUSION AB NPV stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So XVIVO PERFUSION AB NPV technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating XVIVO PERFUSION AB NPV stock shows the buy signal. See more of XVIVO PERFUSION AB NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.